scholarly journals Closed-loop trans-skull ultrasound hyperthermia leads to improved drug delivery from thermosensitive drugs and promotes changes in vascular transport dynamics in brain tumors

Theranostics ◽  
2021 ◽  
Vol 11 (15) ◽  
pp. 7276-7293
Author(s):  
Chulyong Kim ◽  
Yutong Guo ◽  
Anastasia Velalopoulou ◽  
Johannes Leisen ◽  
Anjan Motamarry ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Brain Tumors ◽  
Closed Loop ◽  
Transport Dynamics ◽  
Vascular Transport ◽  
Ultrasound Hyperthermia

The role of U.S. thermal stress in modulating the vascular transport dynamics in the brain tumors

2021 ◽  
Vol 149 (4) ◽  
pp. A119-A119
Author(s):  
Costas Arvanitis ◽  
Chulyong Kim ◽  
Yutong Guo ◽  
Anastasia Velalopoulou
Keyword(s):  
Thermal Stress ◽  
Brain Tumors ◽  
Transport Dynamics ◽  
Vascular Transport ◽  
The Brain

scholarly journals Focused ultrasound in neuro-oncology: the role of the Focused Ultrasound Foundation in driving adoption and innovation

2021 ◽  
Author(s):  
Emily C. Whipple ◽  
Camille A. Favero ◽  
Neal F. Kassell
Keyword(s):  
Drug Delivery ◽  
Brain Tumors ◽  
Focused Ultrasound ◽  
Clinical Evidence ◽  
Neurological Injury ◽  
High Concentration ◽  
Potential Applications ◽  
Tumor Agent

Abstract Introduction Intra-arterial (lA) delivery of therapeutic agents across the blood-brain barrier (BBB) is an evolving strategy which enables the distribution of high concentration therapeutics through a targeted vascular territory, while potentially limiting systemic toxicity. Studies have demonstrated lA methods to be safe and efficacious for a variety of therapeutics. However, further characterization of the clinical efficacy of lA therapy for the treatment of brain tumors and refinement of its potential applications are necessary. Methods We have reviewed the preclinical and clinical evidence supporting superselective intraarterial cerebral infusion (SSJACI) with BBB disruption for the treatment of brain tumors. In addition, we review ongoing clinical trials expanding the applicability and investigating the efficacy of lA therapy for the treatment of brain tumors. Results Trends in recent studies have embraced the use of SSIACI and less neurotoxic chemotherapies. The majority of trials continue to use mannitol as the preferred method of hyperosmolar BBB disruption. Recent preclinical and preliminary human investigations into the lA delivery of Bevacizumab have demonstrated its safety and efficacy as an anti-tumor agent both alone and in combination with chemotherapy. Conclusion lA drug delivery may significantly affect the way treatment are delivered to patients with brain tumors, and in particular GBM. With refinement and standardization of the techniques of lA drug delivery, improved drug selection and formulations, and the development of methods to minimize treatment-related neurological injury, lA therapy may offer significant benefits for the treatment of brain tumors.

139 POSTER Enhanced drug delivery to brain tumors with a new paclitaxel-peptide conjugate

2008 ◽  
Vol 6 (12) ◽  
pp. 45 ◽  
Author(s):  
F. Bichat ◽  
M. Demeule ◽  
B. Lawrence ◽  
O. Raguin ◽  
B. Sourzat ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Brain Tumors

Enzyme and Au nanoparticles encapsulated ZIF-8 for glucose responsive closed-loop drug delivery

2021 ◽  
pp. 130276
Author(s):  
Zichu Yin ◽  
Minjie Lin ◽  
Yan Xu ◽  
Zhenyu Wang ◽  
Yurong Cai ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Closed Loop ◽  
Au Nanoparticles

Drug delivery to brain tumors: physiological and pharmacokinetic aspects of chemotherapy

1986 ◽  
pp. 211-220 ◽  
Author(s):  
Ronald G. Blasberg ◽  
Dennis R. Groothuis ◽  
Donald C. Wright ◽  
Peter Molnar
Keyword(s):  
Drug Delivery ◽  
Brain Tumors

Effect of Tumor Volume on Drug Delivery in Heterogeneous Vasculature of Human Brain Tumors

2019 ◽  
Vol 2 (2) ◽  
Author(s):  
Ajay Bhandari ◽  
Ankit Bansal ◽  
Rishav Jain ◽  
Anup Singh ◽  
Niraj Sinha
Keyword(s):  
Drug Delivery ◽  
Brain Tumors ◽  
Human Brain ◽  
Contrast Agent ◽  
Large Volume ◽  
Interstitial Fluid ◽  
Tumor Volume ◽  
Drug Distribution ◽  
Dce Mri ◽  
Concentration Of Contrast Agent

Drug distribution in tumors is strongly dependent on tumor biological properties such as tumor volume, vasculature, and porosity. An understanding of the drug distribution pattern in tumors can help in enhancing the effectiveness of anticancer treatment. A numerical model is employed to study the distribution of contrast agent in the heterogeneous vasculature of human brain tumors of different volumes. Dynamic contrast enhanced-magnetic resonance imaging (DCE-MRI) has been done for a number of patients with different tumor volumes. Leaky tracer kinetic model (LTKM) is employed to obtain perfusion parameters from the DCE-MRI data. These parameters are used as input in the computational fluid dynamics (CFD) model to predict interstitial fluid pressure (IFP), interstitial fluid velocity (IFV), and distribution of the contrast agent in different tumors. Numerical results demonstrate that the IFP is independent of tumor volume. On the other hand, the IFV increases as the tumor volume increases. Further, the concentration of contrast agent also increases with the tumor volume. The results obtained in this work are in line with the experimental DCE-MRI data. It is observed that large volume tumors tend to retain a higher concentration of contrast agent for a longer duration of time because of large extravasation flux and slow washout as compared to smaller tumors. These results may be qualitatively extrapolated to chemotherapeutic drug delivery, implying faster healing in large volume tumors. This study helps in understanding the effect of tumor volume on the treatment outcome for a wide range of human tumors.

scholarly journals Status Quo and Trends of Intra-Arterial Therapy for Brain Tumors: A Bibliometric and Clinical Trials Analysis

Pharmaceutics ◽  
2021 ◽  
Vol 13 (11) ◽  
pp. 1885
Author(s):  
Julian S. Rechberger ◽  
Frederic Thiele ◽  
David J. Daniels
Keyword(s):  
Drug Delivery ◽  
Clinical Trials ◽  
Brain Tumors ◽  
Phase 1 ◽  
Citation Count ◽  
Tumor Therapy ◽  
The United States ◽  
Blood Brain Barrier Disruption ◽  
Current State ◽  
Brain Barrier Disruption

Intra-arterial drug delivery circumvents the first-pass effect and is believed to increase both efficacy and tolerability of primary and metastatic brain tumor therapy. The aim of this update is to report on pertinent articles and clinical trials to better understand the research landscape to date and future directions. Elsevier’s Scopus and ClinicalTrials.gov databases were reviewed in August 2021 for all possible articles and clinical trials of intra-arterial drug injection as a treatment strategy for brain tumors. Entries were screened against predefined selection criteria and various parameters were summarized. Twenty clinical trials and 271 articles satisfied all inclusion criteria. In terms of articles, 201 (74%) were primarily clinical and 70 (26%) were basic science, published in a total of 120 different journals. Median values were: publication year, 1986 (range, 1962–2021); citation count, 15 (range, 0–607); number of authors, 5 (range, 1–18). Pertaining to clinical trials, 9 (45%) were phase 1 trials, with median expected start and completion years in 2011 (range, 1998–2019) and 2022 (range, 2008–2025), respectively. Only one (5%) trial has reported results to date. Glioma was the most common tumor indication reported in both articles (68%) and trials (75%). There were 215 (79%) articles investigating chemotherapy, while 13 (65%) trials evaluated targeted therapy. Transient blood–brain barrier disruption was the commonest strategy for articles (27%) and trials (60%) to optimize intra-arterial therapy. Articles and trials predominately originated in the United States (50% and 90%, respectively). In this bibliometric and clinical trials analysis, we discuss the current state and trends of intra-arterial therapy for brain tumors. Most articles were clinical, and traditional anti-cancer agents and drug delivery strategies were commonly studied. This was reflected in clinical trials, of which only a single study had reported outcomes. We anticipate future efforts to involve novel therapeutic and procedural strategies based on recent advances in the field.

scholarly journals Contribution of Nanotechnology and Nanomaterials to the Treatment of Diabetic Patients by Aid of Novel Inventions

2020 ◽  
pp. 29-40
Author(s):  
Shiva Najigivi ◽  
Seyedahmadreza Mirmotallebi ◽  
Alireza Najigivi
Keyword(s):  
Diabetes Mellitus ◽  
Drug Delivery ◽  
Human Health ◽  
Carbon Nanostructures ◽  
Closed Loop ◽  
Insulin Injection ◽  
Diabetic Patients ◽  
Temporal Response ◽  
Nanoscience And Nanotechnology ◽  
The Impact

Nanoscience and Nanotechnology are highly growing their significance in diabetic supplies and research nowadays. It is an area that included nanomaterials, nanosensors and nanostructures as well as nanoparticle projects and also their usage in human health research. Particularly, nanotechnology helps to the production of diabetic supplies, materials together with the development of novel glucose and insulin injection devices as well as their measurement sensors by the aid of nanomaterials. These materials mostly could be metal nanoparticles together with carbon nanostructures by nano dimension delivery mechanisms modalities which hold the potential to vividly recover the excellence of life of diabetic patients. Nanoscience and nanotechnology in diabetic research have facilitated and provided more truthful data for identifying diabetes mellitus. It is also worth mentioning that the nanotechnology could highly enhance the impact of drug delivery by addition of nanoscale materials and increase the glucose feeling, temporal response as well as glucose nursing. Furthermore, it is proposing novel nanoscale methods named closed-loop insulin delivery approaches which mechanically release insulin drug in reply to fluctuating blood glucose heights. Besides, the mixture of nanotechnology by medication has shaped a novel field of nanomedicine which could enhance human health level. It is worthwhile to mention that some of the applications of nanotechnology for the treatment of diabetic patients can be the production of diabetic supplies by nanotechnology. One of the most important diabetic instruments that could highly relieve the life of patients these days could be nano diabetic shoes which will describe here. In this research, applications of nanoscience and nanotechnology in treating diabetic patients were discussed.

scholarly journals CADD-06. VISMODEGIB LOADED POLYOXAZOLINE (POx) MICELLES ENHANCE EFFICACY OF VISMODEGIB AND PROLONG MICE SURVIVAL, EMPHASIZE POTENTIAL OF POx MICELLES TO IMPROVE DRUG DELIVERY TO BRAIN TUMORS

2018 ◽  
Vol 20 (suppl_6) ◽  
pp. vi278-vi278
Author(s):  
Duhyeong Hwang ◽  
Chaemin Lim ◽  
Yuling Zhao ◽  
Hedi Liu ◽  
Alexander V Kabanov ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Brain Tumors ◽  
Improve Drug Delivery

scholarly journals Overview of Current Drug Delivery Methods Across the Blood–Brain Barrier for the Treatment of Primary Brain Tumors

CNS Drugs ◽  
2020 ◽  
Vol 34 (11) ◽  
pp. 1121-1131 ◽  
Author(s):  
Rianne Haumann ◽  
Jessica Carvalho Videira ◽  
Gertjan J. L. Kaspers ◽  
Dannis G. van Vuurden ◽  
Esther Hulleman
Keyword(s):  
Drug Delivery ◽  
Brain Tumors ◽  
Blood Brain Barrier ◽  
Brain Barrier ◽  
Delivery Methods ◽  
Primary Brain Tumors ◽  
Current Drug ◽  
Blood Brain
Sign in / Sign up

Export Citation Format

Share Document